These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2451265)

  • 21. Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines.
    Sherritt MA; Gardner J; Elliott SL; Schmidt C; Purdie D; Deliyannis G; Heath WR; Suhrbier A
    Eur J Immunol; 2000 Feb; 30(2):671-7. PubMed ID: 10671225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination for disease.
    Oehen S; Hengartner H; Zinkernagel RM
    Science; 1991 Jan; 251(4990):195-8. PubMed ID: 1824801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell recognition of hepatitis B and C viral antigens.
    Jung MC; Diepolder HM; Pape GR
    Eur J Clin Invest; 1994 Oct; 24(10):641-50. PubMed ID: 7531642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design.
    Lalvani A; Hill AV
    Clin Sci (Lond); 1998 Nov; 95(5):531-8. PubMed ID: 9791038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus.
    Michel F; Hoffenbach A; Langlade-Demoyen P; Guy B; Girard M; Lecocq JP; Wain-Hobson S; Kieny MP; Plata F
    Eur J Immunol; 1988 Dec; 18(12):1917-24. PubMed ID: 2905993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.
    Mauch C; Grimm C; Meckel S; Wands JR; Blum HE; Roggendorf M; Geissler M
    Vaccine; 2001 Oct; 20(1-2):170-80. PubMed ID: 11567762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide vaccines for viral diseases.
    Francis MJ
    Sci Prog; 1990; 74(293 Pt 1):115-30. PubMed ID: 2267573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection.
    Cole GA; Hogg TL; Coppola MA; Woodland DL
    J Immunol; 1997 May; 158(9):4301-9. PubMed ID: 9126992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.
    Jaye A; Magnusen AF; Sadiq AD; Corrah T; Whittle HC
    J Clin Invest; 1998 Dec; 102(11):1969-77. PubMed ID: 9835622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination.
    Kast WM; Brandt RM; Melief CJ
    Eur J Immunol; 1993 May; 23(5):1189-92. PubMed ID: 8386667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
    Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic recombinant vaccines against viral agents.
    Arnon A; Levi R
    Int Arch Allergy Immunol; 1995 Dec; 108(4):321-6. PubMed ID: 7580302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide-induced antiviral protection by cytotoxic T cells.
    Schulz M; Zinkernagel RM; Hengartner H
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):991-3. PubMed ID: 1992491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.
    Klavinskis LS; Whitton JL; Joly E; Oldstone MB
    Virology; 1990 Oct; 178(2):393-400. PubMed ID: 1699348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.
    Lauterbach H; Kerksiek KM; Busch DH; Berto E; Bozac A; Mavromara P; Manservigi R; Epstein AL; Marconi P; Brocker T
    J Virol; 2004 Apr; 78(8):4020-8. PubMed ID: 15047818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes.
    Thomson SA; Elliott SL; Sherritt MA; Sproat KW; Coupar BE; Scalzo AA; Forbes CA; Ladhams AM; Mo XY; Tripp RA; Doherty PC; Moss DJ; Suhrbier A
    J Immunol; 1996 Jul; 157(2):822-6. PubMed ID: 8752934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination.
    Joosten SA; Ottenhoff TH
    Hum Immunol; 2008 Nov; 69(11):760-70. PubMed ID: 18835413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza basic polymerase 2 peptides are recognized by influenza nucleoprotein-specific cytotoxic T lymphocytes.
    Anderson RW; Bennink JR; Yewdell JW; Maloy WL; Coligan JE
    Mol Immunol; 1992 Sep; 29(9):1089-96. PubMed ID: 1495499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.